• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Sotera Health Company

    5/15/26 4:57:53 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    Sotera Health Co

    (Name of Issuer)


    Common Stock, par value $0.01 per share

    (Title of Class of Securities)




    83601L102

    (CUSIP Number)
    03/06/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    WARBURG PINCUS & CO.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    WP XI Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus Private Equity XI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus XI Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus Private Equity XI-B, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus Private Equity XI-C, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Bull Co-Invest L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus XI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    WP Global LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus Partners II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus Partners GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus (Cayman) XI, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus XI-C, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus Partners II (Cayman), L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus (Bermuda) Private Equity GP Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    BERMUDA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    83601L102


    1Names of Reporting Persons

    Warburg Pincus LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sotera Health Co
    (b)Address of issuer's principal executive offices:

    9100 South Hills Blvd, Suite 300, Broadview Heights, OH, 44147
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 6 to Schedule 13G is being filed jointly by (i) Warburg Pincus Private Equity XI, L.P. ("WP XI"), (ii) Warburg Pincus Private Equity XI-B, L.P. ("WP XI-B"), (iii) WP XI Partners, L.P. ("WP XI Partners"), (iv) Warburg Pincus XI Partners, L.P. ("Warburg Pincus XI Partners"), (v) Warburg Pincus Private Equity XI-C, L.P. ("WP XI-C" and, together with WP XI, WP XI-B, WP XI Partners and Warburg Pincus XI Partners, the "WP XI Funds"), (vi) Bull Co-Invest L.P. ("Bull Co-Invest"), (vii) Warburg Pincus XI, L.P. ("WP XI GP"), (viii) WP Global LLC ("WP Global"), (ix) Warburg Pincus Partners II, L.P. ("WPP II"), (x) Warburg Pincus Partners GP LLC ("WPP GP LLC"), (xi) Warburg Pincus & Co. ("WP"), (xii) Warburg Pincus (Cayman) XI, L.P. ("WP XI Cayman GP"), (xiii) Warburg Pincus XI-C, LLC ("WP XI-C LLC"), (xiv) Warburg Pincus Partners II (Cayman), L.P. ("WPP II Cayman"), (xv) Warburg Pincus (Bermuda) Private Equity GP Ltd. ("WP Bermuda GP"), and (xvi) Warburg Pincus LLC ("WP LLC"). The WP XI Funds, Bull Co-Invest L.P. ("Bull Co-Invest"), Bull Holdco L.P. ("Bull Holdco), WP Global, WPP II, WPP GP LLC, WP XI Cayman GP, WP XI-C LLC, WPP II Cayman, WP Bermuda GP, WP Bull Manager, WP LLC and WP are collectively referred to herein as the "Warburg Pincus Entities." WP XI GP is the general partner of each of WP XI, WP XI-B, WP XI Partners and Warburg Pincus XI Partners. WP Global is the general partner of WP XI GP. WPP II is the managing member of WP Global. WPP GP LLC is the general partner of WPP II. WP is the managing member of WPP GP LLC. WP XI Cayman GP is the general partner of WP XI-C. WP XI-C LLC is the general partner of WP XI Cayman GP. WPP II Cayman is the managing member of WP XI-C LLC. WP Bermuda GP is the general partner of WPP II Cayman. WP Bull Manager LLC ("WP Bull Manager") is the general partner of Bull Co-Invest. WP is the managing member of WP Bull Manager. WP LLC is the manager of the WP XI Funds. The WP XI Funds share limited partnership ownership in Bull Holdco on a pro rata basis in accordance with their respective numbers of Contributed Shares. The WP XI Funds, Bull Co-Invest, WP XI GP, WP Global, WPP II, WPP GP LLC, WP XI Cayman GP, WP XI-C LLC, WPP II Cayman, WP Bermuda GP, WP Bull Manager, WP LLC and WP are collectively referred to herein as the "Warburg Pincus Reporting Persons" or "WP Investors."
    (b)Address or principal business office or, if none, residence:

    Warburg Pincus Reporting Persons is 450 Lexington Avenue, New York, New York 10017
    (c)Citizenship:

    See Item 2(a)
    (d)Title of class of securities:

    Common Stock, par value $0.01 per share
    (e)CUSIP No.:

    83601L102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of May 13, 2026, the Warburg Pincus Reporting Persons no longer own any shares of Common Stock. This filing represents an exit filing for the Warburg Pincus Reporting Persons.
    (b)Percent of class:

    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0.00

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    0.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    (1) The Warburg Pincus Reporting Persons are making this single, joint filing because they may be deemed to constitute a "group" within the meaning of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The joint filing agreement among the Warburg Pincus Reporting Persons to file this Amendment No. 6 to Schedule 13G jointly in accordance with Rule 13d-1(k) of the Exchange Act is incorporated by reference as Exhibit 99.1. (2) Each Warburg Pincus Reporting Person expressly disclaims beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) with respect to any shares of Common Stock of the Issuer other than the shares of Common Stock of the issuer owned of record by such Warburg Pincus Reporting Person
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    WARBURG PINCUS & CO.
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    WP XI Partners, L.P.
     
    Signature:/s/ Warburg Pincus XI, L.P.
    Name/Title:Warburg Pincus XI, L.P / General Partner
    Date:05/15/2026
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners II, L.P
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    Warburg Pincus Private Equity XI, L.P.
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti, Partner
    Date:05/15/2026
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    Warburg Pincus XI Partners, L.P.
     
    Signature:/s/ Warburg Pincus XI, L.P.
    Name/Title:Warburg Pincus XI, L.P. / General Partner
    Date:05/15/2026
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    Warburg Pincus Private Equity XI-B, L.P.
     
    Signature:/s/ Warburg Pincus XI, L.P.
    Name/Title:Warburg Pincus XI, L.P. / General Partner
    Date:05/15/2026
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    Warburg Pincus Private Equity XI-C, L.P.
     
    Signature:/s/ Warburg Pincus (Cayman) XI, L.P.
    Name/Title:Warburg Pincus (Cayman) XI, L.P. / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus XI-C, LLC
    Name/Title:Warburg Pincus XI-C, LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners II (Cayman), L.P.
    Name/Title:Warburg Pincus Partners II (Cayman), L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:05/15/2026
     
    Bull Co-Invest L.P.
     
    Signature:/s/ WP Bull Manager LLC
    Name/Title:WP Bull Manager LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Warburg Pincus XI, L.P.
     
    Signature:/s/ WP Global LLC
    Name/Title:WP Global LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    WP Global LLC
     
    Signature:/s/ Warburg Pincus Partners II, L.P.
    Name/Title:Warburg Pincus Partners II, L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    Warburg Pincus Partners II, L.P.
     
    Signature:/s/ Warburg Pincus Partners GP LLC
    Name/Title:Warburg Pincus Partners GP LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    Warburg Pincus Partners GP LLC
     
    Signature:/s/ Warburg Pincus & Co.
    Name/Title:Warburg Pincus & Co. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Partner
    Date:05/15/2026
     
    Warburg Pincus (Cayman) XI, L.P.
     
    Signature:/s/ Warburg Pincus XI-C, LLC
    Name/Title:Warburg Pincus XI-C, LLC / General Partner
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus Partners II (Cayman), L.P.
    Name/Title:Warburg Pincus Partners II (Cayman), L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:05/15/2026
     
    Warburg Pincus XI-C, LLC
     
    Signature:/s/ Warburg Pincus Partners II (Cayman), L.P.
    Name/Title:Warburg Pincus Partners II (Cayman), L.P. / Managing Member
    Date:05/15/2026
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:05/15/2026
     
    Warburg Pincus Partners II (Cayman), L.P.
     
    Signature:/s/ Warburg Pincus (Bermuda) Private Equity GP Ltd.
    Name/Title:Warburg Pincus (Bermuda) Private Equity GP Ltd. / General Partner
    Date:05/15/2026
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:05/15/2026
     
    Warburg Pincus (Bermuda) Private Equity GP Ltd.
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Authorised Signatory
    Date:05/15/2026
     
    Warburg Pincus LLC
     
    Signature:/s/ Harsha Marti
    Name/Title:Harsha Marti / Managing Director, Chief Legal Officer and Head of New Solutions
    Date:05/15/2026
    Exhibit Information

    Exhibit 99.1 Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.* * Incorporated herein by reference to the Agreement of Joint Filing by Warburg Pincus Private Equity XI, L.P., Warburg Pincus XI Partners, L.P., Warburg Pincus Private Equity XI-B, L.P., WP XI Partners, L.P., Warburg Pincus Private Equity XI-C, L.P., Bull Co-Invest L.P., Warburg Pincus XI, L.P., WP Global LLC, Warburg Pincus Partners II, L.P., Warburg Pincus Partners GP LLC, Warburg Pincus & Co., Warburg Pincus (Cayman) XI, L.P., Warburg Pincus XI-C, LLC, Warburg Pincus Partners II (Cayman), L.P., Warburg Pincus (Bermuda) Private Equity GP LTD., and Warburg Pincus LLC ("Warburg Pincus Funds") dated as of February 14, 2022, which was previously filed with the Commission as Exhibit 99.1 to Amendment No. 1 to Schedule 13G filed by the Warburg Pincus Funds on February 14, 2022 with respect to the shares of common stock of Sotera Health Co.

    Get the next $SHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    1/9/2026$24.00Neutral → Overweight
    Piper Sandler
    1/9/2026$24.00Outperform
    RBC Capital Mkts
    12/18/2025Outperform
    William Blair
    11/13/2025$19.00Outperform
    BMO Capital Markets
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    More analyst ratings

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sotera Health upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Sotera Health from Neutral to Overweight and set a new price target of $24.00

    1/9/26 8:33:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    RBC Capital Mkts resumed coverage on Sotera Health with a new price target

    RBC Capital Mkts resumed coverage of Sotera Health with a rating of Outperform and set a new price target of $24.00

    1/9/26 8:12:05 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    William Blair initiated coverage on Sotera Health

    William Blair initiated coverage of Sotera Health with a rating of Outperform

    12/18/25 9:11:03 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    SEC Filings

    View All

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SEC Form SD filed by Sotera Health Company

    SD - Sotera Health Co (0001822479) (Filer)

    5/29/26 4:05:15 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Sotera Health Co (0001822479) (Filer)

    5/22/26 4:09:28 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Company filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Sotera Health Co (0001822479) (Filer)

    5/20/26 4:10:41 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Secondary Offering of Common Stock

    CLEVELAND, May 11, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC) (the "Company") today announced the launch of a secondary offering (the "Offering") of 31,838,253 shares of its common stock, par value $0.01 per share. All 31,838,253 shares are being offered for sale by certain affiliates of Warburg Pincus LLC ("Warburg Pincus") and GTCR LLC ("GTCR") as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering. The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registra

    5/11/26 4:33:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

    Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Compan

    5/5/26 7:03:49 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces Leadership Transition

    Alton Shader, CEO of Viant Medical®, to become CEO and join the Board of Directors, effective May 26, 2026Chairman and CEO Michael B. Petras, Jr. will serve as Executive Chairman of the Board of Directors CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced the appointment of Alton Shader to the role of Chief Executive Officer ("CEO") of the Company, effective May 26, 2026, as part of a planned leadership transition. Mr. Shader will succeed Michael B. Petras, Jr., Chair

    5/5/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klee Ann R. was granted 14,970 shares, increasing direct ownership by 12% to 140,926 units (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 8:27:22 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Chief Executive Officer Shader Alton was granted 579,573 shares (SEC Form 4)

    4 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 5:54:27 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 3 filed by new insider Shader Alton

    3 - Sotera Health Co (0001822479) (Issuer)

    5/27/26 5:47:15 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    View All

    Sotera Health Appoints Richard Kyle to the Board of Directors

    CLEVELAND, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, announced today it has appointed Richard G. Kyle as a new independent director to its Board of Directors. Mr. Kyle will serve as a member of the Leadership Development and Compensation Committee and the Nominating and Corporate Governance Committee of the Board of Directors. Most recently, Mr. Kyle served as President and Chief Executive Officer of The Timken Company ("Timken") (NYSE:TKR), a global manufacturer of bearings, transmissions, and industrial motion produc

    2/5/26 7:30:00 AM ET
    $SHC
    $SON
    $TKR
    Misc Health and Biotechnology Services
    Health Care
    Containers/Packaging
    Consumer Discretionary

    Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

    CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

    1/6/25 4:30:38 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    $SHC
    Financials

    Live finance-specific insights

    View All

    Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook

    Q1 2026 net revenues increased 10.0%, or 6.5% on a constant currency basis, compared to Q1 2025Q1 2026 net income of $27 million or $0.09 per diluted share, compared to a net loss of $13 million or $0.05 per diluted share in Q1 2025Q1 2026 Adjusted EBITDA(1) increased 10.5%, or 6.9% on a constant currency basisQ1 2026 Adjusted EPS(1) of $0.18, an increase of 29% per diluted shareCompany reaffirms full-year 2026 outlook of 5.0% - 6.5% net revenues growth and 5.5% - 7.0% Adjusted EBITDA growth, both on a constant currency basisCompany announced planned CEO transition in a separate release today CLEVELAND, May 05, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Compan

    5/5/26 7:03:49 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Announces First-Quarter 2026 Earnings Release Date

    CLEVELAND, April 21, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first-quarter ended March 31, 2026 before the market opens on Tuesday, May 5, 2026. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's operating and financial results. A live webcast of the conference call and accompanying materials can be accessed via the Investor Relations section of the Company's website at Presentation & Event

    4/21/26 7:46:03 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Sotera Health Delivers 20th Consecutive Year of Revenue Growth and Provides 2026 Outlook

    2025 net revenues increased 5.7% to $1.164 billion, compared to 2024, or 5.2% on a constant currency basis2025 net income increased to $78 million or $0.27 per diluted share, compared to net income of $44 million, or $0.16 per diluted share, in 20242025 Adjusted EBITDA(1) increased 8.2% to $594 million, compared to 2024, or 7.8% on a constant currency basis2025 Adjusted EPS(1) of $0.86, an increase of $0.16 per diluted share, compared to 2024Full-year 2026 outlook: net revenues growth of 5.0% to 6.5% and Adjusted EBITDA growth of 5.5% to 7.0%, on a constant currency basis CLEVELAND, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC),

    2/24/26 7:00:00 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:51:55 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/14/24 4:50:09 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sotera Health Company

    SC 13G/A - Sotera Health Co (0001822479) (Subject)

    11/12/24 5:53:58 PM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care